MARKET

CDTTW

CDTTW

CDT Equity Inc,
NASDAQ
0.0122
+0.0020
+19.61%
Closed 15:30 05/13 EDT
OPEN
0.0093
PREV CLOSE
0.0102
HIGH
0.0122
LOW
0.0093
VOLUME
83.10K
TURNOVER
0
52 WEEK HIGH
0.0217
52 WEEK LOW
0.0050
MARKET CAP
--
P/E (TTM)
-0.0000
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CDT last week (0504-0508)?
Weekly Report · 3d ago
CDT Equity Unit Sarborg Files Parent Covering Two Established Compounds Within The Cystic Fibrosis Market
Benzinga · 6d ago
CDT Equity announces AZD5904 progresses into patent cooperation treaty phase
TipRanks · 05/07 04:50
CDT advances AZD5904 into global PCT patent phase
PUBT · 05/06 12:32
Weekly Report: what happened at CDT last week (0427-0501)?
Weekly Report · 05/04 10:12
CDT Equity director Ulrik K. Olsen files initial beneficial ownership statement
PUBT · 05/01 00:17
CDT Equity Announces Board Changes and New Chairperson
TipRanks · 04/27 20:30
CDT Equity appoints Ulrik Olsen to board after Lewis-Hall resignation
PUBT · 04/27 20:12
More
About CDTTW
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis (HT and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).

Webull offers Conduit Pharmaceuticals Inc stock information, including NASDAQ: CDTTW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTTW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDTTW stock methods without spending real money on the virtual paper trading platform.